Why Did Novo Nordisk Stock Plummet Recently

Key Takeaways

• Novo Nordisk's stock recently plunged 21% after a weak 2026 outlook, driven by intense competition and U.S. pricing pressures.
• While Eli Lilly has gained significant market share with superior GLP-1 drugs, Novo Nordisk's oral Wegovy and robust pipeline offer long-term growth catalysts.
• The market appears to have overcorrected, pricing NVO for a permanent decline, which may present a compelling entry point for long-term investors.

---

Why Did Novo Nordisk Stock Plummet Recently?

Novo Nordisk (NVO) shares have experienced a significant downturn, plunging by as much as 21% over the past month, with a notable 15% drop on February 4, 2026, following its latest earnings report. This sharp correction wiped out the year-to-date rally and sent the stock trading near $49.57, a steep discount from its 52-week high of $93.80. The immediate catalyst for this dramatic sell-off wasn't a poor Q4 2025 performance – in fact, the company beat both earnings and revenue estimates, posting $1.00 EPS and $12.3 billion in revenue. Instead, the market reacted violently to Novo Nordisk’s "downright awful" 2026 guidance.

The Danish pharmaceutical giant projected an adjusted sales and operating profit decline of 5-13% at constant exchange rates (CER) for 2026. This outlook stands in stark contrast to its solid 2025 performance, which saw sales growth of 10% and operating profit growth of 6% at CER. Management explicitly attributed the grim 2026 forecast to several critical headwinds. These include intensifying competition, particularly from Eli Lilly, significant pricing pressure in the crucial U.S. market, and the widespread use of cheaper compounded semaglutide alternatives.

Adding to the pressure, Novo Nordisk faces patent expiries for semaglutide in key international markets like Brazil, Canada, and China. The company also highlighted a $4.2 billion reversal of U.S. 340B rebate provisions, a one-off benefit that boosted 2025 results but will not recur in 2026. This combination of competitive threats, pricing erosion, and non-recurring benefits paints a challenging picture for the coming year, leading investors to rapidly re-evaluate the company's near-term growth trajectory. The market's verdict was swift and severe, pricing in a significant reset of the growth narrative.

Is Eli Lilly's Dominance a Permanent Threat to Novo Nordisk?

The competitive landscape in the GLP-1 drug market has undeniably shifted, with Eli Lilly (LLY) emerging as a formidable rival to Novo Nordisk. Lilly’s tirzepatide-based drugs, Mounjaro (for Type 2 Diabetes) and Zepbound (for obesity), have rapidly gained ground, surpassing the sales of Novo Nordisk's Wegovy and Ozempic in 2025. This is a critical development, especially considering Lilly’s Zepbound launched in December 2023, much later than Wegovy. By February 2025, Lilly had captured a dominant 60% of the U.S. GLP-1 market share, a significant reversal from Novo Nordisk's earlier lead.

A key factor in Lilly's success is the perceived superior efficacy of tirzepatide. A head-to-head clinical trial conducted by Lilly in 2024 demonstrated that patients on Zepbound lost an average of 50 pounds over 72 weeks, compared to 33 pounds for those on Wegovy. This clinical advantage, coupled with strong physician and patient preference, has been a major driver of Lilly's market share gains. Furthermore, Lilly has been aggressive in building out its manufacturing infrastructure, committing over $50 billion to new sites and expansions since 2020, addressing supply constraints that have sometimes plagued Novo Nordisk.

The diverging 2026 outlooks of the two companies underscore this competitive dynamic. While Novo Nordisk braces for a sales decline, Eli Lilly forecasts robust revenue growth of 20-25%, reaching $80-83 billion. This bullish projection from Lilly, driven by its blockbuster GLP-1 medicines, has further solidified investor confidence in its market leadership. While Novo Nordisk still holds a substantial 62% market volume share in GLP-1 drugs, this moat is under direct threat from Lilly's aggressive strategy and clinical superiority. The market is clearly betting on Lilly extending its advantage, making Novo Nordisk's fight to regain ground a "must-win battle."

What's the Bull Case for Novo Nordisk Amidst the Headwinds?

Despite the recent stock plunge and intense competition, Novo Nordisk presents a compelling long-term bull case, particularly for investors willing to look beyond the immediate 2026 headwinds. The company's strategic pivot towards an oral formulation of its blockbuster weight-loss drug, Wegovy, is a significant game-changer. Launched in the U.S. in January 2026, oral Wegovy has seen explosive early adoption, with 170,000 patients using the pill after just four weeks and approximately 50,000 prescriptions in a single week. This rapid uptake demonstrates a powerful demand tailwind and a vast addressable market for a more convenient, non-injectable GLP-1 option.

While the 2026 guidance reflects lower U.S. pricing for Wegovy, partly due to an agreement with the U.S. government to cut drug prices and increased competition, the long-term strategy is to offset per-unit price declines with massive volume growth. CEO Mike Doustdar's comment that "people should expect that it goes down before it comes back up" suggests management views 2026 as a trough year, with a recovery driven by the oral pill's market penetration. The introduction of oral GLP-1s is expected to significantly increase the addressable population for obesity medications, potentially expanding the market beyond current projections.

Beyond oral Wegovy, Novo Nordisk boasts a robust and diversified R&D pipeline that could drive future growth. Key candidates include amycretin, a dual GLP-1 and amylin analogue in Phase 3 studies for both subcutaneous and oral formulations, with interim data expected next year. CagriSema, which combines semaglutide with cagrilintide, is another promising next-generation drug. Furthermore, UBT251, an investigational triple agonist, is in early development. These pipeline assets, alongside potential label expansions for Ozempic (e.g., peripheral artery disease) and Wegovy (e.g., higher dose, MASH indication), could provide significant catalysts beyond 2026, diversifying revenue streams and strengthening Novo Nordisk's competitive edge in the cardiometabolic space.

Is the Market Overreacting to Novo Nordisk's 2026 Outlook?

The market's reaction to Novo Nordisk's 2026 guidance, particularly the 21% stock drop, appears to be an overcorrection, pricing the company as if the projected decline is permanent rather than a temporary trough. The stock's current P/E ratio of 13.32 is notably below its 12-month average of 18.73 and its 5-year average of 22.2. This depressed valuation suggests extreme pessimism, implying that the market has already absorbed the worst-case scenario of a double-digit drop in sales and profit for 2026.

Consider the context: Novo Nordisk delivered strong 2025 results, with 10% sales growth and 6% operating profit growth at CER. The 2026 guidance, while disappointing, formalizes known headwinds like pricing pressure and competition, which were already anticipated to some extent. The magnitude of the projected 5-13% decline, while an 8% downside to prior consensus, might not fully account for the long-term volume potential of the oral Wegovy pill, which has shown exceptional early adoption. This creates a potential asymmetry in the risk/reward profile.

While the immediate pain of lower prices and rebate reversals is real, the company's underlying financial engine remains powerful. Novo Nordisk boasts strong margins, with a gross margin of 81.0%, operating margin of 41.3%, and net margin of 33.1%. Its return on equity (ROE) is an impressive 61.1%, and return on invested capital (ROIC) stands at 29.5%. These robust profitability metrics, combined with a healthy dividend yield of 3.8% and a manageable debt-to-equity ratio of 0.67, indicate a fundamentally sound business. The market's focus on the immediate contraction might be overlooking the company's ability to navigate this period and capitalize on the massive long-term growth in the GLP-1 market.

What Does This Mean for Investors?

For investors, Novo Nordisk's current situation presents a classic "expectation gap" scenario. The market has priced in a severe downturn for 2026, but the long-term growth narrative, particularly around the oral GLP-1 market and a robust pipeline, remains largely intact. This divergence between short-term pain and long-term potential creates a compelling opportunity for those with a patient, long-term investment horizon. The stock is trading at a significant discount to its historical valuation, suggesting that much of the bad news is already baked into the price.

However, investors should be prepared for continued volatility in the near term. The next critical data point will be Novo Nordisk's Q1 2026 earnings report on May 6, 2026. This will provide the first official update on how the company is tracking against its 2026 guidance. Investors should scrutinize whether sales and profit declines are stabilizing or if the competitive and pricing pressures are proving more severe than anticipated. Any signs that the decline is moderating or that the oral Wegovy rollout is exceeding expectations could serve as a powerful catalyst for a rebound.

Three key areas to watch are:

1. Oral Wegovy's Commercial Traction: Monitor prescription trends and patient adoption rates for the oral pill. Sustained strong volume growth, even at lower per-unit prices, will be crucial for offsetting revenue declines.
2. U.S. Pricing Stability: Any indication that pricing pressure in the U.S. market is bottoming out or that the impact of 340B rebates is less severe than expected would be a significant positive surprise.
3. Pipeline Progress: Keep an eye on clinical trial readouts for next-generation GLP-1s like amycretin and CagriSema. Positive data could reignite investor enthusiasm and provide new growth drivers beyond the current semaglutide franchise.

The current market sentiment offers an attractive entry point for investors who believe in the long-term potential of the GLP-1 market and Novo Nordisk's ability to innovate and adapt. While 2026 will be a challenging year, the depressed valuation and strong underlying fundamentals suggest that the pain may already be priced in, leaving room for a significant rebound if the company can successfully navigate this transitional period.

---

Novo Nordisk is facing a pivotal year, but its long-term prospects in the booming GLP-1 market, especially with the promising oral Wegovy and a deep pipeline, remain compelling. For patient investors, the recent sell-off could be a rare opportunity to acquire shares of a fundamentally strong company at a significant discount, positioning for a potential rebound as the market shifts its focus from short-term headwinds to long-term growth.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.